Skip to main content
dana-farber.org

Turning Promise Into Progress

 

How new cancer treatments reach patients and help shape the next cycle of discovery

Susana M. Campos, MD, MPH

Susana M. Campos, MD, MPH

The journey to a new cancer treatment rarely follows a straight line. At Dana-Farber, it often runs from laboratory bench to patient bedside and back again.

A discovery in the laboratory may spark an idea for a new treatment. Researchers then test that idea in clinical trials with patients. If the treatment proves safe and effective, the U.S. Food and Drug Administration may approve it for wider use. Even then, the work continues. Researchers bring what they learn from patients back to the lab, where new questions can lead to the next trial.

"Think of it as a relay race," said Susana M. Campos, MD, MPH, clinical director of Gynecologic Oncology at Dana-Farber. "Each clinical trial provides valuable insights that help shape and inform the next trial."

Susana M. Campos, MD, MPH Quote
Erica L. Mayer, MD, MPH

Erica L. Mayer, MD, MPH

Teams at Dana-Farber's Susan F. Smith Center for Women’s Cancers work at every stage of this long relay to improve treatments for breast and gynecologic cancers. They build on trials that have led to FDA approvals, lead studies that could change how patients are treated, and test whether effective treatments could help more people if given earlier. They also analyze tumor samples and other data to learn who may benefit most, why some cancers stop responding, and how to better tailor treatments to each patient's tumor.

"As clinicians, we are motivated every day to try and make a difference for each and every one of our patients," said Erica L. Mayer, MD, MPH, director of breast cancer clinical research at Dana-Farber's Breast Oncology Center. "Problems or challenges we encounter in clinic spark the next trial and inspire us to keep pushing forward."

Looking Beyond FDA Approval

After more than a decade of work, Sara M. Tolaney, MD, MPH, chief of Breast Oncology at Dana-Farber, and her colleagues reached a major milestone. The FDA approved sacituzumab govitecan as a first-line treatment for advanced triple-negative breast cancer.

Metastatic triple-negative breast cancer may be more challenging to treat due to its more proliferative growth pattern and historically fewer treatment options. Sacituzumab govitecan, an antibody-drug conjugate that precisely delivers a cancer-killing drug to tumor cells, had already improved outcomes when given later in metastatic disease. Yet many patients who receive their first treatment may not go on to receive a second.

Sara M. Tolaney, MD, MPH

Sara M. Tolaney, MD, MPH

"If a very effective drug is only approved as your second-line or later therapy, many people aren't going to be able to get it," Tolaney said. "For us, moving our most effective therapeutic into that first-line setting is particularly critical."

Tolaney and her colleagues led two phase 3 trials to find out whether the drug could help more patients if given sooner. ASCENT-03 compared sacituzumab govitecan with chemotherapy as an initial treatment for patients who were not candidates for immunotherapy. ASCENT-04 compared sacituzumab govitecan plus pembrolizumab with chemotherapy plus pembrolizumab in patients whose tumors were positive for PD-L1, a marker of potential response to immunotherapy.

In both trials, patients treated with sacituzumab govitecan went longer without their cancer worsening. The results led the FDA to approve sacituzumab govitecan as a first-line treatment on June 24, 2026.

Tolaney is now looking ahead. How well will the treatment work after immunotherapy? Could giving it earlier prevent more breast cancers from becoming metastatic?

ASCENT-05 is testing sacituzumab govitecan with immunotherapy in patients with early-stage triple-negative breast cancer who still have cancer after their initial treatment. Researchers want to know whether the combination can prevent more cancers from returning and spreading.

"We're very fortunate that we have a very tight integration with our basic scientists and our clinical researchers, so that when there is a really important finding, we are able to smoothly move it from the lab into the clinic," Tolaney said. "I don't think very many places can do this."

Bench to Bedside and Back

Research across Dana-Farber is turning promising ideas into new treatment options for patients with advanced breast cancer.

In the phase 3 PATINA trial, designed and led by Dana-Farber investigators, adding palbociclib, a CDK-4/6 inhibitor, to standard maintenance therapy for patients with hormone receptor-positive, HER2-positive metastatic breast cancer extended the median time before cancer worsened from 29.1 months to 44.3 months. The FDA approved the combination on June 24, 2026.

Other promising treatments are not far behind. Hormone receptor-positive breast cancers can respond well to treatments that block estrogen, but the estrogen receptor may change, or tumor cells may activate other signals that allow them to keep growing. To overcome this emerging resistance, Mayer is leading the phase 3 evERA trial, which is testing giredestrant, a new oral endocrine therapy, plus everolimus, another oral targeted anticancer therapy, against standard hormone therapy plus everolimus.

In evERA, patients who received giredestrant plus everolimus had nearly double the time before their cancer worsened, compared to those receiving standard treatment. This effect was even stronger in patients whose tumors had an ESR1 resistance mutation, an important cause of hormone therapy resistance.

Because both medicines are pills, patients may need fewer office visits and have more freedom "to do the things they need to do in their lives like work, travel, and care for their family," Mayer said.

The FDA is reviewing an application for the combination, with a decision expected in December 2026.

"The story doesn’t end with FDA approval," Mayer said. "It just starts a new chapter."

Filipa Lynce, MD

Filipa Lynce, MD

Some potential treatments are much earlier in the journey from bench to bedside. Filipa Lynce, MD, director of Dana-Farber's Inflammatory Breast Cancer Program and a member of the Mellen and Eisenson Family Center for BRCA and Related Genes, is leading trials for patients with BRCA-associated breast cancer and inflammatory breast cancer, a rare and aggressive form of the disease.

One of those investigator-led efforts began with an observation in mice. When BRCA-associated tumors stopped responding to olaparib, immune cells called macrophages gathered around them and appeared to help the cancer resist treatment. Drugs targeting macrophages already existed, so the finding led to a trial asking whether those drugs could keep olaparib working longer in patients.

"I could not develop these trials without the work done in the lab by my colleagues Jennifer Guerriero and Geoffrey Shapiro," Lynce said. "It's collaborative work from the initial idea until you enroll the last patient."

Lynce is also leading trials for rare cancers that can be overlooked in larger trials. One is TRUDI, which is testing an antibody-drug conjugate with immunotherapy in inflammatory breast cancer.

"If you don't develop clinical trials for these rare diseases or subtypes that only affect a small number of patients, you might miss the opportunity to learn about what is unique in these patients," she said. "We are moving away from a model that is one-size-fits-all."

A More Tailored Approach

A deeper understanding of tumor biology is also reshaping how gynecologic cancers are treated.

"The treatment of endometrial cancer has changed dramatically over the course of the past several years," Campos said. "We now have four categories of endometrial cancer, and we can now look at treatments that are dedicated to each and every one of these categories."

NRG-GY035, a new phase 3 trial that recently opened to patients, is testing combinations of chemotherapy, pembrolizumab, and bevacizumab in patients with advanced or recurrent endometrial cancer whose tumors have molecular features linked to poorer outcomes.

"Instead of treating all women the same way, we're going to look at their molecular characteristics and tailor treatments to them," said Campos, who is leading the trial.

Many of these new approaches begin with ideas from Dana-Farber investigators. About 45% of Dana-Farber's gynecologic cancer trials are initiated by its researchers, rather than pharmaceutical companies, said Ursula A. Matulonis, MD, chief of gynecologic oncology at Dana-Farber.

Ursula Matulonis, MD, and Rebecca Porter, MD, PhD

Ursula Matulonis, MD, and Rebecca Porter, MD, PhD

"We want to offer novel therapies to all of our patients," Matulonis said. "That is really afforded by this clinical trial portfolio that is driven by unique and interesting ideas from faculty that lead to investigator-initiated trials."

Panos Konstantinopoulos, MD, PhD

Panos Konstantinopoulos, MD, PhD

One example is the RESOLVE trial led by Panos Konstantinopoulos, MD, PhD, director of translational research in Gynecologic Oncology at Dana-Farber. The trial is testing treatments for patients with recurrent or persistent estrogen receptor-positive endometrial cancer.

Guided by laboratory findings, his team added metformin, an inexpensive diabetes drug that affects cancer growth signals, to the hormone-blocking drug letrozole and the targeted drug abemaciclib. With the three-drug combination, patients went a median of 19 months without their cancer worsening. Twelve percent had complete responses, meaning no cancer could be detected.

"These were durable responses," Konstantinopoulos said. "We're very excited about that." His team is now testing a similar combination with gedatolisib instead of metformin. Because gedatolisib blocks a cancer growth pathway more completely than metformin, researchers hope it will produce even better results.

Even as that trial moves forward, the team is looking for clues about what they should study next. The researchers are collecting tumor biopsies before, during, and after treatment, tracking tumor DNA in patients' blood, and growing miniature laboratory models of individual tumors. Their goal is to learn why treatments stop working and which drugs or combinations might work next.

None of this progress in bringing new treatments to patients would be possible without the patients themselves, Mayer said.  

"We're not able to identify new treatments or have new therapies approved without being able to do the trials that demonstrate this is a step forward," Mayer said. "Supporting the research and the work that happens at Dana-Farber, both in the research lab as well as in the clinical trial space, is immensely important and helps to fuel the engine that allows us to make progress."

By Linda Wang